oundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing
Lucid positioned to submit EsoGuard for Technical Assessment and coverage under foundational LCD when sufficient clinical utility data available later this year
https://finance.yahoo.com/news/lucid-diagnostics-provides-newly-published-164500762.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.